



April 28, 2022

The General Manager

Pakistan Stock Exchange Limited
Stock Exchange Building,
Stock Exchange Road,
Karachi

Dear Sir,

Sub: Disclosure of Price Sensitive Information – Proposed Investment in sanofi-aventis Pakistan Limited (Company)

In accordance with Sections 96 and 131 of the Securities Act, 2015 and Clause 5.6.1 of the Rule Book issued by the Pakistan Stock Exchange Limited ("PSX"), this is in continuation of our earlier letter dated December 20, 2021, in which we announced that Sanofi Foreign Participations B.V. gave the Investor Consortium an opportunity to evaluate and conduct a due diligence for a potential transaction for the purchase of entire 52.87% shareholding of Sanofi Foreign Participants B.V held in the Company.

Today, Packages Limited made a public announcement of the finalization of purchase price and terms and conditions of the Proposed Transaction between the Investor Consortium and Sanofi Foreign Participants B.V. upon conclusion of due diligence. The Investor Consortium is comprised of Packages Limited, IGI Investments (Private) Limited and affiliates of Arshad Ali Gohar Group. The Investor Consortium is led by Packages Limited.

A disclosure form as required under S.R.O. 143/(1)/2012 dated December 5, 2012 read with Sections 96 and 131 of the Securities Act, 2015 is also enclosed as an Annexure hereto.

You are requested to disseminate the information to the Members of the Exchange accordingly.

Yours sincerely,

A handwritten signature in blue ink that reads "Abu Bakar" with a flourish underneath.

Muhammad Abu Bakar Siddiq

Company Secretary

Encl: As above

- Cc: (i) **Executive Director/HOD**, Offsite-II Department, Supervision Division, Securities & Exchange Commission of Pakistan, 63, NIC Building, Jinnah Avenue, Blue Area, Islamabad
(ii) **Director/HOD**, Company Law Division, Securities & Exchange Commission of Pakistan, NIC Building, Jinnah Avenue, Blue Area, Islamabad; and
(iii) **Company Registration Office**, Securities & Exchange Commission of Pakistan, 4th Floor, State Life Building No. 2, Wallace Road, Karachi

sanofi-aventis Pakistan limited

Plot No. 23, Sector No. 22, Korangi Industrial Area, Karachi-74900, Pakistan
PABX: +92-21-35060221-35 Fax: +92-21-35060358 Web: sanofi.com.pk



SANOFI

DISCLOSURE FORM **INTERMS OF SECTIONS 96 AND 131 OF THE SECURITIES ACT, 2015**

Name of Company	sanofi-aventis Pakistan Limited
Date of Report	28 April 2022
Name of Company as specified in The Memorandum	sanofi-aventis Pakistan Limited
Company's Registered Office	Plot No. 23, Sector-22, Korangi Industrial Area, Karachi
Contact Information	Tel: +92 21 35060221-35

Disclosure of price sensitive / inside information by listed company in terms of Section 96 and 131:

This is in continuation of our earlier letter dated December 20, 2021 in which we announced that Sanofi Foreign Participations B.V. gave the Investor Consortium an opportunity to evaluate and conduct a due diligence for a potential transaction for the purchase of entire 52.87% shareholding of Sanofi Foreign Participants B.V. held in sanofi-aventis Pakistan Limited. The Investor Consortium is comprised of Packages Limited, IGI Investments (Private) Limited and affiliates of Arshad Ali Gohar Group. The Investor Consortium is led by Packages Limited.

In this regard, please note that the Investor Consortium announced that it has finalized the purchase price and terms and conditions of the Proposed Transaction with Sanofi Foreign Participants B.V. upon conclusion of the due diligence process as approved by the Board of Directors of Packages Limited in its meeting held on April 27, 2022. The negotiated purchase price for the Proposed Transaction is Rs. 940 / share (excluding transaction costs) and Packages Limited expects to acquire 35% of equity stake in Sanofi Pakistan. The remaining shareholding i.e. 17.87% (Remaining Shareholding) is expected to be taken by other members of the Investor Consortium. Packages Limited shall also be committed to purchase Remaining Shareholding to the extent not taken-up by any other member of the Investor Consortium along with such shares as may be offered under the mandatory public offer in terms of applicable take-over laws.

The Proposed Transaction remains subject to signing of transaction documents between the parties, including a Share Purchase Agreement, and fulfillment of applicable contractual and legal conditions (including for investment in associates and under take-over laws) and applicable corporate and regulatory approvals.

Pursuant to the requirements of the Securities Act, 2015, the Company has duly caused this form/statement to be signed on its behalf by the undersigned hereunto duly authorized.

Intimation of decision of the listed company to delay disclosure of inside information in terms of Section 96(4).

NIL

Disclosure of inside information by listed company where the listed company or person acting on its behalf discloses inside information to third party in terms of Section 131.

NIL

sanofi-aventis Pakistan limited

Plot No. 23, Sector No. 22, Korangi Industrial Area, Karachi-74900, Pakistan
PABX: +92-21-35060221-35 Fax: +92-21-35060358 Web: sanofi.com.pk



SANOFI

- Disclosure of transactions conducted by persons discharging managerial responsibilities within a listed company or persons closely associated with them.**

NIL

For and on behalf of
sanofi-aventis Pakistan Limited

Muhammad Abu Bakar Siddiq
Company Secretary

sanofi-aventis Pakistan limited

Plot No. 23, Sector No. 22, Korangi Industrial Area, Karachi-74900, Pakistan
PABX: +92-21-35060221-35 Fax: +92-21-35060358 Web: sanofi.com.pk